❇️ Retatrutide vs. Eloralintide: Why the Amylin Pathway Might Be the Smarter Play Retatrutide is arguably the most powerful weight loss compound to have emerged from clinical trials so far. A triple agonist hitting GLP-1, GIP, and glucagon receptors simultaneously, it produced weight loss numbers in Phase 2 that exceeded even tirzepatide — roughly 24% mean body weight reduction at the highest doses over 48 weeks. The data is real, and it's impressive. So why would a researcher consider eloralintide instead? The answer lies not in dismissing what retatrutide does, but in understanding what it costs to do it — and why eloralintide offers a fundamentally different, complementary pathway that may deliver comparable outcomes with a cleaner pharmacological profile and better long-term flexibility. ❇️ What Retatrutide Is Actually Doing Retatrutide (Eli Lilly, Phase 3 trials) stacks three receptor agonisms into a single molecule: GLP-1 receptor activation (appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion), GIP receptor activation (amplified satiety signaling, improved insulin sensitivity, reduced adipose inflammation), and glucagon receptor activation (increased hepatic fat oxidation, elevated energy expenditure, thermogenesis). The glucagon component is what separates it from tirzepatide and semaglutide — it turns up the body's metabolic furnace, burning more energy at rest and accelerating fat clearance from the liver. ➡ That glucagon agonism is also where the complexity begins. Glucagon is a counter-regulatory hormone — it raises blood glucose, promotes hepatic gluconeogenesis, and elevates heart rate. In a carefully balanced triple agonist like retatrutide, the GLP-1 component partially offsets the glucose-raising effects of glucagon. ➡ But that balancing act introduces pharmacological unpredictability. The three pathways interact, the net metabolic effect is a composite of competing signals, and the side effect profile — while generally manageable in trials — is broader and more variable than a single-pathway compound. GI adverse events, heart rate elevation, and titration complexity all reflect the fact that three receptor systems are being activated simultaneously.

🚨 Anyone that's been around the research peptide community has likely spent the last two years WARNING everyone that peptides are on the sh*t list of Big Pharma and the 3-letter agencies, and it's only a matter of time before something happens... 🚨 That day may finally be here. Over the last few weeks, I've followed renown figures in the peptide space whom have had multiple conversations with peeps at the highest levels of peptide manufacturing. And when I say the highest, I do mean the HIGHEST. And they've all said the same thing - things are BAD. 🚨To the point that many of them think that we have until January or February 2027 until RUO peptides go bye-bye (if we're lucky). Big Pharma is done playing around. They're coming after EVERYONE. (Peptide Resource Center has already received FDA letters and had its payment processors shut down 2 weeks ago!) And they're using the influence they exert over the 3-letter agencies to do it. In certain states, clinicians have been told that if they even DISCUSS these compounds with their patients, they're at risk of losing their license 😳 So, what can you do to prepare? 1️⃣ Stock up !!!